23-Apr-2026
Top Sangamo Therapeutics Insiders Quietly Unload Shares in Back-to-Back Moves
TipRanks (Thu, 23-Apr 10:01 PM ET)
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/23/26?
TipRanks (Thu, 23-Apr 10:23 AM ET)
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 4/22/26?
TipRanks (Wed, 22-Apr 10:19 AM ET)
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 4/21/26?
TipRanks (Tue, 21-Apr 11:00 AM ET)
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/20/26?
TipRanks (Mon, 20-Apr 9:20 AM ET)
Globe Newswire (Mon, 30-Mar 4:01 PM ET)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Globe Newswire (Thu, 19-Mar 4:03 PM ET)
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Globe Newswire (Mon, 9-Mar 8:05 AM ET)
Globe Newswire (Tue, 3-Feb 4:05 PM ET)
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
Globe Newswire (Tue, 3-Feb 9:10 AM ET)
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
Sangamo Therapeutics trades on the NASDAQ stock market under the symbol SGMO.
As of April 23, 2026, SGMO stock price was flat at $0.25 with 6,789,119 million shares trading.
SGMO has a beta of 0.22, meaning it tends to be less sensitive to market movements. SGMO has a correlation of 0.00 to the broad based SPY ETF.
SGMO has a market cap of $94.78 million. This is considered a Micro Cap stock.
Last quarter Sangamo Therapeutics reported $14 million in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-24 million and missed earnings estimates by -$.09.
In the last 3 years, SGMO traded as high as $3.18 and as low as $.21.
The top ETF exchange traded funds that SGMO belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, ITOT.
SGMO has underperformed the market in the last year with a price return of -67.2% while the SPY ETF gained +35.8%. SGMO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.0% and +0.1%, respectively, while the SPY returned +3.1% and +4.8%, respectively.
SGMO support price is $.24 and resistance is $.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMO shares will trade within this expected range on the day.